ImmunOs Therapeutics AG

ImmunOs Therapeutics Secures $11M to Advance IOS-1002 Cancer Immunotherapy Trial

- ImmunOs Therapeutics has raised $11 million in Series C financing to support the clinical development of its lead program, IOS-1002. - IOS-1002 is a novel immunotherapy agent targeting multiple immune checkpoints for the treatment of advanced solid tumors. - The funding will facilitate the completion of the Phase Ia dose escalation study of IOS-1002 as a monotherapy and in combination with pembrolizumab. - IOS-1002 modulates the tumor microenvironment by activating innate and adaptive immune cells, potentially enhancing the efficacy of existing immunotherapies.